DBTRG-05MG (ATCC® CRL-2020)

Organism: Homo sapiens, human  /  Cell Type: glial cell  /  Tissue: brain  /  Disease: glioblastoma

Organism Homo sapiens, human
Tissue brain
Cell Type glial cell
Product Format frozen
Morphology fibroblast
Culture Properties adherent
Biosafety Level 1
Disease glioblastoma
Age 59 years
Gender female
Ethnicity Caucasian
Karyotype near tetraploid; range 87 to 91; most cells were missing copies of chromosome 10 and had extra copies of chromosome 7
Derivation
The DBTRG-O5MG (Denver Brain Tumor Research Group 05) cell line was established from tissue from a patient with glioblastoma multiforme who had been treated with local brain irradiation and multidrug chemotherapy.
Clinical Data
59 years
Caucasian
female

Antigen Expression
Class I antigen expressed
Receptor Expression
epidermal growth factor (EGF)
Genes Expressed
vimentin; S-100 protein; neuron specific enolase
Cellular Products
vimentin; S-100 protein; neuron specific enolase
Comments

The cells are negative for platelet derived growth factor (PDGF), neuronal cell adhesion molecule (NCAM), glial fibrillary acid protein (GFAP) and class II antigen (HLA DR).

No loss of heterozygosity in the p53 tumor suppressor gene was detected.

Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
  • fetal bovine serum to a final concentration of 10%
  • additional 30 mg/L L-proline
  • additional 35 mg/L L-cystine
  • additional 3.57 g/L HEPES
  • 15 mg/L hypoxanthine
  • 1 mg/L adenosine triphosphate
  • 10 mg/L adenine
  • 1 mg/L thymidine

Subculturing
Remove medium, add fresh 0.25% trypsin, rinse and remove trypsin. Let the flask sit at room temperature (or incubate at 37°C) until the cells detach. Add fresh medium, aspirate and dispense into new flasks.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
STR Profile
Amelogenin: X
CSF1PO: 10,11
D13S317: 9
D16S539: 10,12
D5S818: 12,13
D7S820: 11
THO1: 7,8
TPOX: 8
vWA: 15,16
Name of Depositor CA Kruse
References

Kruse CA, et al. Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vitro Cell. Dev. Biol. 28A: 609-614, 1992. PubMed: 1331021

Koochekpour S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 57: 5391-5398, 1997. PubMed: 9393765

Debinski W, et al. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 271: 22428-22433, 1996. PubMed: 8798406

Basic Documentation
References

Kruse CA, et al. Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vitro Cell. Dev. Biol. 28A: 609-614, 1992. PubMed: 1331021

Koochekpour S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 57: 5391-5398, 1997. PubMed: 9393765

Debinski W, et al. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 271: 22428-22433, 1996. PubMed: 8798406